- No public price.
- Not disclosed
- Not disclosed
- —
- —
- AT
Radiology
contextflow
by contextflow GmbH · AT
ADVANCE Chest CT for nodule detection, lung tissue analysis and similar-case search on chest CT, CE-marked. Acquisition by 4DMedical announced June 2026.
On this page
22/100
Not rated: too little independent evidence yet.
- Regulatory & Compliance0/28
No FDA clearance listed
- Clinical Integration0/6.6
No EHR integrations listed
- Evidence Strength12.7/26
3 peer-reviewed papers
- Vendor & Market3/18
Seed-stage or unfunded
- Sentiment & Transparency2.5/5
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance0/18
No FDA clearance listed
- HIPAA / SOC2 / BAA0/10
No public HIPAA/SOC2/BAA attestation
- EHR integrations (count)0/4
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/2
None of the top-3 EHRs covered
- Peer-reviewed papers13/18
3 peer-reviewed papers
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal3/12
Seed-stage or unfunded
- Years in market0/6
Founded year not recorded
- Pricing transparency3/5
Pricing on request, no public amounts
ADVANCE Chest CT for nodule detection, lung tissue analysis and similar-case search on chest CT, CE-marked. Acquisition by 4DMedical announced June 2026.
No public price.
Evidence record
No FDA decision cited in our research as of November 2, 2026.
3 studies on PubMed: 3 other, published 2026. Read the literature summary
- Score computed November 2, 2026, method 1.2.0
- Review written November 2, 2026
MedAI Verdict, contextflow record, https://medaiverdict.com/tools/contextflow, version November 2, 2026
Bottom line
contextflow GmbH of Vienna sells ADVANCE Chest CT, CE-marked software for lung nodules and lung tissue patterns on chest CT, and SEARCH, its radiology image search product. It fits a European radiology department reading chest CT for suspected lung cancer, interstitial lung disease and COPD. A US department has no cleared option here, because the vendor's own page says DETECT is "not yet cleared for clinical use" in the US. On June 1, 2026, 4DMedical announced a deal to acquire the company. No price is public.
Who is behind it?
contextflow describes itself as a spinoff of the Medical University of Vienna, with its address on Margaretenstrasse in Vienna. On June 1, 2026, 4DMedical Limited (ASX: 4DX, Melbourne) announced what it calls a "binding agreement to acquire contextflow GmbH." Price and close date were not stated. The CEO, Markus Holzer, becomes General Manager of 4DMedical Europe, and the announcement does not say whether the contextflow brand and products continue.
What do the vendor's pages say ADVANCE Chest CT includes?
The vendor describes ADVANCE Chest CT as computer-aided detection support for suspected lung cancer, interstitial lung disease and COPD, running directly in the radiologist's native viewer. Its pages name DETECT, which finds solid, part-solid and non-solid nodules from 4 to 30 mm and refers to Fleischner 2017, Lung-RADS 1.1 and RECIST. TIMELINE reports growth percentage and volume doubling time across prior scans. INSIGHTS draws anomaly heatmaps and quantifies affected volume for seven findings: consolidation, effusion, emphysema, ground-glass, honeycombing, pneumothorax and reticular pattern. iCAC estimates coronary calcium volume and an Agatston score. ADVANCE Chest CT also covers qualitative analysis of 19 image patterns with reference cases. SEARCH, listed as its own product, retrieves similar cases in 3D.
What does the vendor state about integration and regulation?
A CE mark appears on ADVANCE Chest CT with no class given, and the vendor links a DICOM conformance statement. No PACS or RIS vendor and no deployment model is named. ISO, GDPR, HIPAA and SOC 2 are absent from the pages. The home page also shows CE-badged partner products, RevealAI-Lung and CINA-iPE, and the maker of those two is not stated there, so they cannot be attributed to contextflow.
What is the evidence?
The vendor cites a European Radiology paper from July 2022 for "validated average report reading time savings 31%". That 31% is the only quantitative performance claim on the product page, and no sensitivity or specificity figures are given for DETECT.
Radiologist testimonials on the home page, from Erasmus MC, Freiburg University Medical Center, NHS SW London Imaging Network, the Medical University of Innsbruck, Leiden UMC, the Medical University of Mainz and Vienna General Hospital, are selected by the vendor. Partner logos for Boehringer Ingelheim, Roche, NVIDIA and GE carry no stated customer relationship.
The verdict
A European department reading chest CT for nodules and interstitial lung disease is the buyer ADVANCE Chest CT addresses, and it would be buying from a company whose ownership may change under the announced deal. The only performance number is the vendor's 31% reading-time saving, and a US department has no cleared product to buy.
Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | Not stated | Not stated | No public price. |
Source: vendor pricing page. Last checked November 2, 2026.
What deploys cleanly
Carries CE per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
What the literature says
3 peer-reviewed studies indexed on PubMed evaluate contextflow in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.
- Non-contiguous computed tomography lung scans can be manipulated to permit artificial intelligence analyses for interstitial lung disease in systemic sclerosis. (opens in new tab)
- Baron M, Nguyen Q, Kovacina B, et al.· Biol Methods Protoc· 2026
- Artificial intelligence (AI) can analyse high-resolution CT lung scans (HRCT) in various interstitial lung diseases (ILDs), including systemic sclerosis (SSc). Older HRCT lung scans may have been saved as small DICOM file sets consisting of non-contiguous slices. These are not amenable to AI analyses. Our aim was to develop and test a method of rebuilding small non-contiguous sets of HRCT lung slices into larger sets of contiguous slices that could be analysed by AI programs. We deleted sets of DICOM files from 14 large DICOM file set scans from SSc patients and were left with a scan with abo…
- Low-dose vs standard-dose photon-counting CT for myopathy-associated interstitial lung disease: a prospective feasibility study. (opens in new tab)
- Zhu Z, Xu K, Pang Y, et al.· Eur Radiol· 2026
- To evaluate the clinical utility of photon counting computed tomography (PCCT)-derived quantitative parameters for assessing interstitial lung disease (ILD) burden in patients with inflammatory idiopathic myopathy (IIM), comparing standard-dose (SD) and tin-filtered low-dose (LD) protocols, and to assess the added value of ultrathin reconstructions. In this single-centre prospective study (September 2023-November 2024), outpatients with IIM-ILD underwent two consecutive PCCT scans. Quantitative ILD features were extracted using a commercial deep-learning software (ContextFlow ADVANCE Chest CT…
- Automated quantitative analysis can support the identification of progressive pulmonary fibrosis in fibrotic interstitial lung disease. (opens in new tab)
- Janska E, Dixon G, Page J, et al.· BMJ Open Respir Res· 2026
- Identifying progression in fibrotic interstitial lung disease (f-ILD) is essential for treatment decisions and prognostication. Quantitative CT (qCT) may improve detection of progressive pulmonary fibrosis (PPF). We evaluated whether routine qCT enhances identification of disease progression. We conducted a retrospective observational study of patients presenting to an ILD service over 2 years. Patients with f-ILD who underwent two CT scans within 24 months prior to ILD multidisciplinary team (ILD-MDT) review were included. CTs were initially reported by a mixed pool of radiologists and subse…
Other radiology
See the full radiology ranking
Siemens Healthineers AI-Rad Companion
by Siemens Healthineers
AI-Rad Companion: Chest CT, Chest X-ray, Brain MR, Prostate MR and Organs RT (radiotherapy contouring) modules, delivered through teamplay.
No public price on the vendor page.|FDA 510(k) (multiple) / CE Mark (MDD/MDR. MDR status not verified)
GE HealthCare AI Suite
by GE HealthCare
Portfolio of separately cleared AI-enabled GE HealthCare devices and software, including AIR Recon DL, Sonic DL, Critical Care Suite, Caption AI and icobrain.
No public price. Products are sold with scanners or as scanner options, on enterprise quotes.|FDA 510(k) (multiple)
Aidoc
by Aidoc
Clinical AI platform (aiOS) with FDA-cleared triage, notification and quantification algorithms for radiology and neurovascular care.
Private offer only. No trial is stated.|FDA 510(k) (multiple) / EU MDR 2017/745
Viz.ai
by Viz.ai
Care coordination platform with FDA-cleared imaging AI for stroke, vascular and cardiac conditions.
No public price. Sold to health systems after a demo request.|FDA 510(k) (multiple) / FDA De Novo (ContaCT, Viz HCM)